FDA clears Phase 1 trial of GC1130A for Sanfilippo type A
GC Biopharma and Novel Pharma plan to initiate a Phase 1 clinical trial this year to test the safety and tolerability of GC1130A, an investigational enzyme replacement therapy that the companies are developing for Sanfilippo syndrome type A. The announcement follows the U.S. Food and Drug Administration…